Construction of a bivalent vaccine against anthrax and smallpox using the attenuated vaccinia virus KVAC103.
Adjuvants, Immunologic
Animals
Anthrax
/ prevention & control
Antibodies, Bacterial
/ blood
Antibodies, Viral
/ blood
Bacillus anthracis
/ genetics
Mice
Smallpox
/ prevention & control
Vaccines, Attenuated
/ genetics
Vaccines, Combined
/ immunology
Vaccines, Synthetic
/ immunology
Vaccinia virus
/ genetics
Anthrax
Cholera toxin
IL-15
Smallpox
Vaccinia virus
Journal
BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981
Informations de publication
Date de publication:
08 03 2021
08 03 2021
Historique:
received:
31
08
2020
accepted:
09
02
2021
entrez:
9
3
2021
pubmed:
10
3
2021
medline:
30
10
2021
Statut:
epublish
Résumé
Anthrax and smallpox are high-risk infectious diseases, and considered as potential agents for bioterrorism. To develop an effective countermeasure for these diseases, we constructed a bivalent vaccine against both anthrax and smallpox by integrating a gene encoding protective antigen (PA) of Bacillus anthracis to the genome of the attenuated vaccinia virus strain, KVAC103. Immunization with this bivalent vaccine induced antibodies against both PA and vaccinia virus in a mouse model. We also observed that the efficacy of this vaccine can be enhanced by combined immunization with immunoadjuvant-expressing KVAC103. Mouse groups co-immunized with PA-expressing KVAC103 and either interleukin-15 (IL-15) or cholera toxin subunit A (CTA1)-expressing KVAC103 showed increased anti-PA IgG titer and survival rate against B. anthracis spore challenge compared to the group immunized with PA-expressing KVAC103 alone. We demonstrated that the attenuated smallpox vaccine KVAC103 is an available platform for a multivalent vaccine and co-immunization of immunoadjuvants can improve vaccine performance.
Sections du résumé
BACKGROUND
Anthrax and smallpox are high-risk infectious diseases, and considered as potential agents for bioterrorism. To develop an effective countermeasure for these diseases, we constructed a bivalent vaccine against both anthrax and smallpox by integrating a gene encoding protective antigen (PA) of Bacillus anthracis to the genome of the attenuated vaccinia virus strain, KVAC103.
RESULTS
Immunization with this bivalent vaccine induced antibodies against both PA and vaccinia virus in a mouse model. We also observed that the efficacy of this vaccine can be enhanced by combined immunization with immunoadjuvant-expressing KVAC103. Mouse groups co-immunized with PA-expressing KVAC103 and either interleukin-15 (IL-15) or cholera toxin subunit A (CTA1)-expressing KVAC103 showed increased anti-PA IgG titer and survival rate against B. anthracis spore challenge compared to the group immunized with PA-expressing KVAC103 alone.
CONCLUSIONS
We demonstrated that the attenuated smallpox vaccine KVAC103 is an available platform for a multivalent vaccine and co-immunization of immunoadjuvants can improve vaccine performance.
Identifiants
pubmed: 33685392
doi: 10.1186/s12866-021-02121-5
pii: 10.1186/s12866-021-02121-5
pmc: PMC7938549
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antibodies, Bacterial
0
Antibodies, Viral
0
Vaccines, Attenuated
0
Vaccines, Combined
0
Vaccines, Synthetic
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
76Subventions
Organisme : Korea Centers for Disease Control and Prevention
ID : 2016-NG45002-00
Organisme : Korea Centers for Disease Control and Prevention
ID : 2017-NG45002-00
Organisme : Korea Centers for Disease Control and Prevention
ID : 4840-302-210-13
Références
Infect Immun. 2007 Jan;75(1):408-16
pubmed: 17074845
Methods Mol Biol. 2010;626:287-309
pubmed: 20099135
Scand J Immunol. 2006 Feb;63(2):97-105
pubmed: 16476008
Curr Gene Ther. 2008 Apr;8(2):97-120
pubmed: 18393831
J Gen Virol. 2008 Dec;89(Pt 12):2954-2964
pubmed: 19008380
Osong Public Health Res Perspect. 2012 Sep;3(3):170-6
pubmed: 24159510
Vaccine. 2008 Sep 19;26(40):5188-95
pubmed: 18462844
FEMS Immunol Med Microbiol. 2005 Aug 1;45(2):331-9
pubmed: 16009541
Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3392-7
pubmed: 12626740
Viruses. 2014 Jul 17;6(7):2735-61
pubmed: 25036462
Clin Infect Dis. 2000 Jun;30(6):843-50
pubmed: 10880299
Immunol Cell Biol. 1998 Jun;76(3):280-7
pubmed: 9682972
Vaccine. 1995 Dec;13(18):1779-84
pubmed: 8701593
Mol Aspects Med. 2009 Dec;30(6):490-502
pubmed: 19729034
J Immunol. 1999 Feb 15;162(4):2432-40
pubmed: 9973526
Vaccine. 2019 Jun 27;37(29):3820-3824
pubmed: 31151800
Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):18091-6
pubmed: 20921397
Microbes Infect. 2012 Mar;14(3):247-61
pubmed: 22064066
J Virol. 2007 Aug;81(16):8774-83
pubmed: 17553867
Clin Vaccine Immunol. 2008 Jan;15(1):131-7
pubmed: 18045883
Vaccine. 2008 Feb 26;26(9):1243-52
pubmed: 18243429
Clin Infect Dis. 2007 Jul 15;45 Suppl 1:S68-72
pubmed: 17582574
Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5676-81
pubmed: 24706798